Prostate Cancer
68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG.
September 2, 2024
Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer.
August 30, 2024
The 340B Program and High-Risk Prescribing of Oral Targeted Therapies for Advanced Prostate Cancer.
August 30, 2024
Prostate Cancer Early Detection in the European Union and UK.
August 30, 2024
Targeting PLOD2 suppresses invasion and metastatic potential in radiorecurrent prostate cancer.
August 30, 2024
PARP inhibitors alone or in combination for prostate cancer.
August 30, 2024
Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
August 29, 2024
5-α Reductase Inhibitors and Prostate Cancer Mortality.
August 29, 2024
Mortality from prostate cancer in the years 2007-2021 in North Rhine-Westphalia, Germany.
August 29, 2024
Appropriateness of Imaging for Low-Risk Prostate Cancer-Real World Data from the Pennsylvania Urologic Regional Collaboration (PURC).
August 29, 2024
Prior Negative Biopsy, PSA Density, and Anatomic Location Impact Cancer Detection Rate of MRI-Targeted PI-RADS Index Lesions.
August 29, 2024
Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer center.
August 28, 2024